14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ANL vs SANA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SANA Captures Overall Composite Edge (44.3 HOLD vs 48.3 HOLD), While ANL Leads 3–2 on Growth & Valuation Pillars
SANA Overall Winner
6-Pillar Tally: ANL 3 – 2 SANA (1 Tie)
Matrix Metrics: ANL 5 – 3 SANA
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (44.3/100 HOLD vs. 48.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. ANL trades at $10.03 (N/M Forward P/E, -123.5% operating margin) versus SANA at $1.88 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY).
Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs SANA. Trailing 12-month operating profitability (ANL -123.5% vs SANA 0.0%) and valuation multiples (ANL N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $683.3M market capitalization and -123.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SANA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ANL vs SANA Key Questions & Quantitative Answers
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (44.3/100 HOLD vs. 48.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. ANL trades at $10.03 (N/M Forward P/E, -123.5% operating margin) versus SANA at $1.88 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY). Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANL leads the Growth & Scale pillar: ANL posts +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANL generates $18M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, ANL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.
ANL screens cheaper on headline valuation multiples. ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.8x EV/Revenue (-119.9% EBITDA margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANL (-20.2% ROE) versus SANA (-79.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.64β · 81% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.